Targeting siRNA Missiles to Her2+ Breast Cancer
Annual rept. 15 May 2008-14 May 2009
CEDARS-SINAI MEDICAL CENTER LOS ANGELES CA
Pagination or Media Count:
The most significant findings here are that HerPBK10 protects siRNA from serum nuclease-mediated degradation, T7 transcribed siRNA is more cytotoxic than synthetic siRNA when delivered to HER2 breast cancer cells by HerPBK10 in vitro, HerPBK10 directs siRNA-mediated cytotoxicity to HER2 but not HER2- cells in vitro, the HerPBK10 carrier preferentially accumulates in HER2 tumors in vivo when delivered systemically intravenously, and cytotoxicity is associated with siRNA-mediated induction of IFN-alpha.
- Anatomy and Physiology
- Medicine and Medical Research